Clinical Trial Update: Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating anti-CD22 CAR T cells in pediatric and young adult patients with recurrent or refractory CD22-expressing B-cell malignancies (including…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-precursor Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Anti-CD22 CAR-T cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: NHL, Large Cell Lymphoma | Phase 1 | Status: COMPLETED